OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Cardiology is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	732
Antibody treatment to deplete transthyretin amyloid deposits in the heart	531
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	455
LIPC variant in combined hypocholesterolaemia	373
Intravascular imaging improves outcomes	336
Injectable and conductive cardiac patch	311
Travelling with heart failure: risk assessment and practical recommendations	291
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	287
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	279
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	274
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	266
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	265
Genetics and mechanisms of thoracic aortic disease	261
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	253
Abbreviating DAPT reduces the risk of bleeding	240
Alternative defibrillation strategies improve outcomes	226
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	218
Electron microscopy of cardiac 3D nanodynamics: form, function, future	217
Defining iron deficiency in patients with heart failure	213
Detection of subclinical hypertrophic cardiomyopathy	206
Think Aorta: aortic dissection awareness and perspectives from the patient	203
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	203
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	203
Hallmarks of cardiovascular ageing	189
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	177

A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	173
Neuromodulation reduces inflammation in HFpEF	173
Extracellular matrix in vascular homeostasis and disease	170
Decongestion in heart failure: medical and device therapies	169
Preparticipation screening reduces SCD in young athletes	164
Increased degradation of desmosomal proteins in ACM	155
CSDE1 regulates LDL receptor levels	154
Catheter ablation improves outcomes in patients with AF and end-stage HF	149
No benefit of apoA-I infusion after myocardial infarction	147
LDL-cholesterol lowering with obicetrapib	146
Graded exercise therapy should not be recommended for patients with post-exertional malaise	146
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	146
Prevention of atherosclerosis from childhood	128
Targeting immune cell recruitment in atherosclerosis	127
The oral microbiome in the pathophysiology of cardiovascular disease	124
Tailored therapeutics for cardiomyopathies	124
Reactive oxygen species in hypertension	121
Colchicine in acute coronary syndromes: the present and the possible future	117
Treatment of mild chronic hypertension in pregnancy reduces pre-eclampsia risk	112
RNA interference lowers triglyceride levels	110
Modelling pre-eclampsia and its cardiovascular effects	106
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	104
Donor macrophages influence rejection of transplanted hearts	101
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	99
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	97
Cardiac sarcomere turnover by unidirectional replacement of proteins	97
Promising novel siRNA for the treatment of hypertension	96
Semaglutide is beneficial in patients with HFpEF and obesity	95
Evidence does not support the reduction of added sugar intake from all food sources	90
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	90
Global epidemiology of heart failure	89
BP management with a village-doctor-led strategy	87
Single-cell profiles of CHD and CM	84
An epigenome editing approach induces durable silencing of Pcsk9	82
CV benefits of finerenone in T2DM and CKD	81
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	79
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	78
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	78
The role of the molecular autopsy in sudden cardiac death in young individuals	77
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation	77
Development of a miniature, bioresorbable, light-activated pacemaker	75
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	74
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	74
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	73
Heart transplantation: advances in expanding the donor pool and xenotransplantation	73
New insights into dietary cholesterol absorption	71
CNR1 antagonism attenuates cannabis-induced atherosclerosis	71
Efferocytosis in atherosclerosis	71